Mandibular repositioning devices (MRD)

Mandibular repositioning devices are often used as an alternative treatment for Obstructive Sleep Apnoea (OSA).1 Rather than using continuous positive airway pressure (CPAP) therapy or undergoing upper airway surgery, patients with MRDs can experience efficient reduction of sleep apnoea symptoms with a simple oral device.2

We at ResMed value your patient’s therapy comfort and efficacy during treatment. That’s why we continue to innovate, designing next generation Mandibular Repositioning Devices that are smaller, more comfortable, functional and easy-to-use.

Learn more about the cutting-edge technology behind our MRD below.

Narval™ CC

Narval CC is an innovative, custom-made MRD device engineered to offer patients greater comfort than ever. Our thin, lightweight design boasts advanced CAD/CAM technology, which means the latest in computer-aided design (CAD) and computer-aided manufacturing (CAM), to produce the perfect fit for your patient.

Watch our video on Narval CC to find out about the CAD/CAM manufacturing process

\

     

Interim results of ORCADES, ResMed’s five-year multicentre study of mandibular repositioning devices, have already proven the high efficacy and compliance behind our oral therapy3, given the following:

  • Innovative, traction-based design retains the mandible in a protruded position rather than pushing it forward like most MRDs, thus relieving stress on the temporomandibular joint (TMJ)
  • Discreet, lightweight design minimises irritation and optimises tongue space
  • Patented articulation allows for natural jaw movement

The unique design of Narval CC is based on breakthrough technology. While CAD process enhances customisation and precision for comfort, CAM technology optimises material for durability. Plus, easy titration allows you to adjust the protrusion of your patient’s oral device for a comfortable therapy experience. 

References

  • 01

    Dookun R. 18-month assessment of 54 patients referred for treatment of anti-social snoring [AHI ≤30/hr] with a custom mandibular repositioning device (MRD).

  • 02

    Geraads et al. First intention management of obstructive sleep apnea syndrome (OSAS) by custom-made mandibular advancement device: the medium-term results. Prospective study by the General Hospital Pneumologists College (CPHG). Rev Pneumol Clin 2010; 66(5):284-292.

  • 03

    Meurice et al. “ORCADES: a prospective cohort study of severe obstructive sleep apnoea (OSA) patients receiving second line-treatment with a mandibular repositioning device (MRD).” Eur Resp J 2013; 42(Suppl. 57):1056S.

This product may not be available in all countries.